Borrelia burgdorferi, the bacteria that cause Lyme disease, are shown surrounded by red blood cells against a light green background.

Bacteria that cause Lyme disease hide from the immune system’s first line of defense to cause disease.

credit: iStock/Dr_Microbe

Lipoproteins hide Lyme bacteria from the immune system

Scientists identified two proteins that help Lyme bacteria evade detection by the human complement system, paving the way for new therapeutics and vaccine targets.
| 4 min read
Written byStephanie DeMarco, PhD

Like spies sneaking across enemy lines, the bacteria that cause Lyme disease have a world-class disguise: an invisibility cloak of lipoproteins. Lyme bacteria (Borrelia burgdorferi sensu lato) interact with their hosts — whether ticks, humans, or other animals — via lipoproteins on their cell surfaces. But because B. burgdorferi are difficult to genetically manipulate and are evolutionarily distant from other better-studied bacteria, scientists still don’t understand how the bacteria use each of these lipoproteins.

When they bite a human, ticks transfer Borrelia burgdorferi bacteria into a person’s bloodstream. There, bacteria must defend themselves against the host’s immune system to survive and cause disease.
Credit: iStock/zilli

Using a cell line of B. burgdorferi that completely lacks lipoproteins, scientists systematically added back one surface lipoprotein at a time and identified two proteins that helped the bacteria evade detection by the human complement system, the first line of defense for the immune system. These findings will inform the development of new therapeutics and vaccine targets for Lyme disease (1).

The complement system consists of proteins in blood serum that recognize invading microbes and set off a cascade of steps to neutralize them. Because B. burgdorferi travel between their tick and mammalian hosts via a bloodmeal, their first threat to survival is from the complement system.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Stephanie DeMarco, PhD Headshot

    Stephanie joined Drug Discovery News as an Assistant Editor in 2021. She earned her PhD from the University of California Los Angeles in 2019 and has written for Discover Magazine, Quanta Magazine, and the Los Angeles Times. As an assistant editor at DDN, she writes about how microbes influence health to how art can change the brain. When not writing, Stephanie enjoys tap dancing and perfecting her pasta carbonara recipe.

    View Full Profile

Here are some related topics that may interest you:

Published In

September 2022
Volume 18 - Issue 9 | September 2022

September 2022

September 2022

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A syringe positioned horizontally above a small vial labeled “cancer vaccine” against a solid purple background.
Rapid DNA-to-mRNA workflows help scientists keep pace with rapidly evolving cancer through personalized vaccines. 
Futuristic 3D human figure surrounded by medical technology and data visuals.
Understand how a human-relevant in vitro model can be used to improve next generation risk assessment (NGRA).
Point-cloud style digital liver illustration with branching vessels on a dark teal background.
Explore the role of microphysiological systems in advancing human-relevant liver toxicity testing and mechanistic evaluation.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue